Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Molnupiravir  COVID-19 treatment studies for Molnupiravir  C19 studies: Molnupiravir  Molnupiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality -47% Improvement Relative Risk Torti et al. Molnupiravir for COVID-19 EARLY TREATMENT Is early treatment with molnupiravir beneficial for COVID-19? Prospective study of 29,553 patients in Italy (Feb - Apr 2022) Study compares with paxlovid, results vs. placebo may differ Higher mortality with molnupiravir (p=0.00014) Torti et al., Elsevier BV, doi:10.2139/ssrn.4444431 Favors molnupiravir Favors paxlovid

Real-Life Comparison of Mortality in Non-Hospitalised Patients with SARS-CoV-2 Infection at Risk for Clinical Progression Treated with Molnupiravir or Nirmatrevir Plus Ritonavir During the Omicron Era in Italy: A Nationwide, Observational Study

Torti et al., Elsevier BV, doi:10.2139/ssrn.4444431 (Preprint)
Torti et al., Real-Life Comparison of Mortality in Non-Hospitalised Patients with SARS-CoV-2 Infection at Risk for Clinical.., Elsevier BV, doi:10.2139/ssrn.4444431 (Preprint)
May 2023   Source   PDF  
  All Studies   Meta
Prospective study of 17,977 outpatients treated with molnupiravir and 11,576 treated with paxlovid, showing significant mortality with both treatments, and lower mortality with paxlovid.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer [Hadj Hassine, Swanstrom]. See [Fountain-Jones, Sanderson,] for analysis of variants potentially created by molnupiravir.
This study includes molnupiravir and paxlovid.
risk of death, 47.1% higher, HR 1.47, p < 0.001, treatment 17,977, control 11,576, adjusted per study, inverted to make HR<1 favor treatment, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Torti et al., 10 May 2023, prospective, Italy, preprint, 24 authors, study period 8 February, 2022 - 30 April, 2022, this trial compares with another treatment - results may be better when compared to placebo.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperMolnupiravirAll
Abstract: Real-life comparison of mortality in non-hospitalised patients with SARS- iew ed CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrevir plus ritonavir during the Omicron era in Italy: a nationwide, observational study pe er re v Carlo Torti1₸, Pier Paolo Olimpieri2,3, Paolo Bonfanti4, Carlo Tascini5, Simone Celant2, Danilo Tacconi6, Emanuele Nicastri7, Evelina Tacconelli8, Bruno Cacopardo9, Alessandro Perrella10, Giovanni Battista Buccoliero11, Giustino Parruti12, Matteo Bassetti13,14, Carlo Biagetti15, Andrea Giacometti16, Elke Maria Erne17, Maria Frontuto18, Massimiliano Lanzafame19, Summa Valentina2, Alessandra Spagnoli3, Annarita Vestri3, Giovanni Di Perri20, Pierluigi Russo2† and Giorgio Palù2† ₸ Corresponding author † These authors contributed equally to this work 1Department of Medical and Surgical Sciences, “Magna Graecia” University, Catanzaro, Pr ep rin tn ot Italy. 2Italian Medicines Agency, Via del Tritone 181, 00187 Rome, Italy. 3Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy. 4Fondazione IRCCS San Gerardo dei Tintori – University of Milano-Bicocca, Monza, Italy. 5Department of medicine (DAME), Infectious Diseases Clinic, Udine University Hospital, Udine, Italy. 6 Department of Specialised and Internal Medicine, Infectious Diseases Unit, San Donato Hospital, Arezzo, Italy. 7 National Institute for Infectious Disease Lazzaron Spallanzani, IRCCS Via portuense 292 00149 Rome, Italy. 8 Infectious Diseases, Department of Diagnostic and Public Health, University of Verona, 37129 Verona, Italy. 9 Department of Internal and Experimental Medicine, University of Catania School of Medicine, Catania, Italy. 10 Division Emerging Infectious Disease and High Contagiousness, D. Cotugno Hospital, 80131 Naples, Italy. 11 Infectious Diseases Unit, San Giuseppe Moscati Hospital, Azienda Sanitaria Locale Taranto, 74121 Taranto, Italy. 12 Department of Medicine, Infectious Disease Unit, Pescara General Hospital, Pescara, Italy. 13 Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy. 14 Infectious Diseases Unit, Policlinico San Martino Hospital—IRCCS, Genoa, Italy. 15 Unit of Infectious disease Infermi Hospital, AUSL Romagna, Rimini, Italy. 16 Azienda Ospedaliera Universitaria, Ospedali Riuniti di Ancona, Ancona, Italy. 17 Azienda sanitaria dell’Alto Adige, Central Hospital of Bolzano, Department of Infectious Disease, Italy. 18 Infectious Diseases Unit – A.O.R. San Carlo - Potenza, Italy. 19 Department of Medical, Infectious Diseases Unit, Santa Chiara Hospital, Trento, Italy. 20 University of Torino, Department of Medical Sciences at the Unit of Infectious Diseases, Amedeo di Savoia Hospital, Torino, Italy. This preprint research paper has not been peer reviewed. Electronic copy available at: iew ed Background Comparative data on mortality in COVID-19 patients treated with molnupiravir or with nirmatrelvir plus ritonavir are scarce and inconclusive. In particular, no adequately powered studies have demonstrated statistically significant differences in mortality between the two oral antivirals. We therefore aimed to provide a comparison of all-cause mortality in community-dwelling COVID-19 patients treated during the Omicron era. pe er re v Methods In this observational study we used data collected in the nationwide, population-based, cohort of patients registered in the database of the..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop